Your browser doesn't support javascript.
loading
External validation and longitudinal application of the DO-GAP index to individualise survival prediction in idiopathic pulmonary fibrosis.
Chandel, Abhimanyu; King, Christopher S; Ignacio, Rosalinda V; Pastre, Jean; Shlobin, Oksana A; Khangoora, Vikramjit; Aryal, Shambhu; Nyquist, Alan; Singhal, Anju; Flaherty, Kevin R; Nathan, Steven D.
Afiliación
  • Chandel A; Department of Pulmonary and Critical Care, Walter Reed National Military Medical Center, Bethesda, MD, USA.
  • King CS; Advanced Lung Disease and Transplant Program, Inova Fairfax Hospital, Falls Church, VA, USA.
  • Ignacio RV; Department of Biostatistics, University of Michigan, Ann Arbor, MI, USA.
  • Pastre J; Service de Pneumologie et Soins Intensifs, Hôpital Européen Georges Pompidou, APHP, Paris, France.
  • Shlobin OA; Advanced Lung Disease and Transplant Program, Inova Fairfax Hospital, Falls Church, VA, USA.
  • Khangoora V; Advanced Lung Disease and Transplant Program, Inova Fairfax Hospital, Falls Church, VA, USA.
  • Aryal S; Advanced Lung Disease and Transplant Program, Inova Fairfax Hospital, Falls Church, VA, USA.
  • Nyquist A; Advanced Lung Disease and Transplant Program, Inova Fairfax Hospital, Falls Church, VA, USA.
  • Singhal A; Advanced Lung Disease and Transplant Program, Inova Fairfax Hospital, Falls Church, VA, USA.
  • Flaherty KR; Division of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, MI, USA.
  • Nathan SD; Advanced Lung Disease and Transplant Program, Inova Fairfax Hospital, Falls Church, VA, USA.
ERJ Open Res ; 9(3)2023 May.
Article en En | MEDLINE | ID: mdl-37228268
ABSTRACT

Background:

The Distance-Oxygen-Gender-Age-Physiology (DO-GAP) index has been shown to improve prognostication in idiopathic pulmonary fibrosis (IPF) compared to the Gender-Age-Physiology (GAP) score. We sought to externally validate the DO-GAP index compared to the GAP index for baseline risk assessment in patients with IPF. Additionally, we evaluated the utility of serial change in the DO-GAP index in predicting survival.

Methods:

We performed an analysis of patients with IPF from the Pulmonary Fibrosis Foundation-Patient Registry (PFF-PR). Discrimination and calibration of the two models were assessed to predict transplant-free survival and IPF-related mortality. Joint longitudinal time-to-event modelling was utilised to individualise survival prediction based on DO-GAP index trajectory.

Results:

There were 516 patients with IPF from the PFF-PR with available demographics, pulmonary function tests, 6-min walk test data and outcomes included in this analysis. The DO-GAP index (C-statistic 0.73) demonstrated improved discrimination in discerning transplant-free survival compared to the GAP index (C-statistic 0.67). DO-GAP index calibration was adequate, and the model retained predictive accuracy to identify IPF-related mortality (C-statistic 0.74). The DO-GAP index was similarly accurate in the subset of patients taking antifibrotic medications. Serial change in the DO-GAP index improved model discrimination (cross-validated area under the curve 0.83) enabling the personalised prediction of disease trajectory in individual patients.

Conclusion:

The DO-GAP index is a simple, validated, multidimensional score that accurately predicts transplant-free survival in patients with IPF and can be adapted longitudinally in individual patients. The DO-GAP may also find use in studies of IPF to risk stratify patients and possibly as a clinical trial end-point.

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies / Risk_factors_studies Idioma: En Revista: ERJ Open Res Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies / Risk_factors_studies Idioma: En Revista: ERJ Open Res Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos